Tina Weinzierl

This inventor holds 11 USPTO granted patents and 21 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Engmab Sarl. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tina Weinzierl. Retrieved from https://idiyas.com/inventor/tina-weinzierl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 21)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 17(Granted Patents)

Location History:

Schlieren, CH (2018 - 2022)
Eggenwil, CH (2023)
Remetschwil, CH (2024)

Company Filing History:

5 out of 5,028

Hoffmann-La Roche Inc.

Years Active: 2018-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),

2. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

3. 12129306 - Antibodies binding to STEAP-1 (2024-10-29),

4. 11987632 - Antibodies binding to HLA-A2/MAGE-A4 (2024-05-21),

5. 11685790 - Antibodies binding to STEAP-1 (2023-06-27),

6. 11459404 - Bispecific T cell activating antigen binding molecules (2022-10-04),

7. 11180571 - Antibodies binding to STEAP-1 (2021-11-23),

8. 10781258 - Bispecific T cell activating antigen binding molecules (2020-09-22),

9. 10781257 - Bispecific T cell activating antigen binding molecules (2020-09-22),

10. 10683369 - Monoclonal antibodies against BCMA (2020-06-16),

11. 10155815 - Bispecific T cell activating antigen binding molecules (2018-12-18),

Title: Innovations by Inventor Tina Weinzierl

Introduction

Tina Weinzierl, a renowned inventor based in Schlieren, Switzerland, has made significant contributions to the field of biomedicine. With a portfolio of 10 patents, she specializes in developing novel bispecific antigen binding molecules that have the potential to revolutionize treatments for various diseases.

Latest Patents

Tina's latest patents focus on two primary inventions. The first patent involves "T cell activating bispecific antigen binding molecules," which are designed to activate T cells and direct them to specific target cells. This invention encompasses polynucleotides encoding these bispecific molecules, as well as vectors and host cells that carry such polynucleotides. Furthermore, the invention elaborates on methods for producing these molecules and leveraging them in the treatment of diseases.

Her second patent involves "Antibodies binding to STEAP-1." This invention is centered on antibodies that specifically bind to the STEAP-1 protein, including bispecific antigen binding molecules intended for T cell activation. Similar to her previous invention, this patent also includes details on polynucleotides encoding these antibodies, methods for their production, and their therapeutic uses.

Career Highlights

Throughout her career, Tina has made impactful contributions while working with prestigious companies such as Hoffmann-La Roche Inc. and Roche Glycart AG. Her expertise in the field of immunology and biopharmaceuticals enabled her to engage in innovative research and development projects within these organizations.

Collaborations

Tina has collaborated with esteemed colleagues in her field, including Ekkehard Moessner and Christian Klein. These partnerships have facilitated the progression of her research and the successful development of her patented technologies.

Conclusion

Tina Weinzierl stands out as a pioneering inventor in the biotechnology sector. Her innovative patents and collaborations are paving the way for future advancements in the treatment of diseases, demonstrating the essential role that inventors like her play in shaping the landscape of modern medicine.

Profile summary based on public USPTO records.